Rigel Pharmaceuticals Inc. (New)
RIGL Real Time Price USDRecent trades of RIGL by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in RIGL holdings by institutional investors
Quarterly net insider trading by RIGL's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$10,000 Jul 16, 2021 Issue: Health Issues
-
$20,000 Jul 16, 2021 Issue: Health Issues
RIGL Estimated quarterly lobbying spending
RIGL Revenue by Segment or Geography
New RIGL patent grants
-
Patent Title: Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jan. 25, 2022
-
Patent Title: Compositions and methods for inhibition of the jak pathway May. 21, 2019
-
Patent Title: Topical formulation for administering a compound Sep. 11, 2018
-
Patent Title: Pyrazole compounds and method for making and using the compounds May. 29, 2018
-
Patent Title: Gdf-8 inhibitors May. 29, 2018
-
Patent Title: In vivo reporter system May. 15, 2018
-
Patent Title: Compositions and methods for inhibition of the jak pathway Mar. 20, 2018
-
Patent Title: Protein kinase c inhibitors and uses thereof Mar. 13, 2018
-
Patent Title: 2,4-pyrimidinediamine compounds and their uses Mar. 13, 2018
-
Patent Title: Compounds and method for treating autoimmune diseases Feb. 13, 2018
-
Patent Title: Tgf-beta inhibitors Feb. 06, 2018
-
Patent Title: Gdf-8 inhibitors Jan. 30, 2018
-
Patent Title: Screening assay employing dex and gdf8 Dec. 19, 2017
-
Patent Title: Nrf2 activating compounds and uses thereof Dec. 19, 2017
-
Patent Title: Kinase inhibitors and their uses Dec. 05, 2017
-
Patent Title: Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds Sep. 05, 2017
-
Patent Title: Prodrugs of 2,4-pyrimidinediamine compounds and their uses Aug. 22, 2017
-
Patent Title: Compositions and methods for inhibition of the jak pathway Aug. 15, 2017
-
Patent Title: Protein kinase c inhibitors and uses thereof Aug. 15, 2017
-
Patent Title: Treatment for vitiligo Aug. 15, 2017
-
Patent Title: Cycloalkyl substituted pyrimidinediamine compounds and their uses Aug. 08, 2017
-
Patent Title: System and method for high-content oncology assay Jul. 11, 2017
-
Patent Title: Tetrazolones as a carboxylic acid bioisosteres Jul. 11, 2017
-
Patent Title: Pharmaceutical process and intermediates Jul. 04, 2017
-
Patent Title: Protein kinase c inhibitors and uses thereof Jun. 20, 2017
-
Patent Title: Ampk-activating heterocyclic compounds and methods for using the same May. 30, 2017
-
Patent Title: N May. 16, 2017
-
Patent Title: Methods for cyclizing synthetic polymers May. 09, 2017
-
Patent Title: Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases Apr. 18, 2017
-
Patent Title: Compositions and methods for inhibition of the jak pathway Apr. 04, 2017
-
Patent Title: 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents Mar. 21, 2017
-
Patent Title: Compositions and methods for inhibition of the jak pathway Mar. 14, 2017
-
Patent Title: 2,4-pyrimidinediamine compounds and their uses Mar. 07, 2017
-
Patent Title: Compositions and methods for inhibition of the jak pathway Feb. 14, 2017
-
Patent Title: Protein kinase c inhibitors and uses thereof Feb. 14, 2017
-
Patent Title: 2,4-pyrimidinediamine compounds and their uses Jan. 10, 2017
-
Patent Title: Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jan. 03, 2017
-
Patent Title: Gdf-8 inhibitors Dec. 13, 2016
-
Patent Title: Methods for using carboxamide, sulfonamide and amine compounds Dec. 06, 2016
-
Patent Title: 2,4-pyrimidinediamine compounds and their uses Nov. 22, 2016
-
Patent Title: Compositions and methods for inhibition of the jak pathway Nov. 01, 2016
-
Patent Title: Fumarate analogs and uses thereof Oct. 25, 2016
-
Patent Title: Protein kinase c inhibitors and uses thereof Sep. 27, 2016
-
Patent Title: Tetrazolones as a carboxylic acid bioisosteres Sep. 13, 2016
-
Patent Title: 2,4-pyrimidinediamine compounds and their uses Aug. 16, 2016
-
Patent Title: 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them Aug. 09, 2016
-
Patent Title: Whole blood assay for measuring ampk activation Jul. 05, 2016
-
Patent Title: Substituted triazoles useful as axl inhibitors May. 31, 2016
-
Patent Title: Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors May. 31, 2016
-
Patent Title: Synthesis of polycyclic alkaloids May. 31, 2016
Federal grants, loans, and purchases
Estimated quarterly amount awarded to RIGL from public contracts
Recent insights relating to RIGL
Recent picks made for RIGL stock on CNBC
ETFs with the largest estimated holdings in RIGL
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $RIGL stock a Buy, Sell, or Hold?
- What is the price target for $RIGL stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $RIGL stock?
- Who owns the most shares of $RIGL stock?
- What funds own $RIGL stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view RIGL Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
- Address South San Francisco, CA
- Market Cap 838.9 million
- Employees 164
- Industrial Classification Pharmaceutical Preparations